haematology
CRASH Score for Chemotherapy Risk Assessment in Elderly Patients
Predicts risk of severe (grade 3-4) haematological and non-haematological toxicity from chemotherapy in patients aged >= 65 years. Guides toxicity risk counselling and dose modification decisions in older cancer patients.
References
- Extermann M et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012;118(13):3377-3386.
- Mohile SG et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO Guideline for Geriatric Oncology. J Clin Oncol. 2018;36(22):2326-2347.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Fong Clinical Risk Score for Colorectal Cancer Recurrence · Oncology
- Ann Arbor Staging System for Lymphoma · Oncology
- Rai Staging System for CLL · Oncology
- Follicular Lymphoma International Prognostic Index (FLIPI) · Oncology
- International Staging System for Multiple Myeloma (ISS) · Oncology
- CISNE Score for Febrile Neutropenia · Oncology
Drugs
- Dopamine (ICU — Vasopressor/Inotrope) · Catecholamine (Dose-Dependent Vasopressor/Inotrope)
- Hydroxocobalamin (High-Dose — Cyanide Antidote) · Cyanide Antidote (Vitamin B12 Precursor at High Dose)
- Dopamine hydrochloride · Inotrope / vasopressor (dose-dependent)
- Enalapril with hydrochlorothiazide · ACE inhibitor + thiazide diuretic (fixed-dose)
- Amiloride with Bumetanide · Potassium-Sparing Diuretic + Loop Diuretic (Fixed-Dose Combination)
- Amlodipine with Valsartan · Calcium-Channel Blocker + ARB (Fixed-Dose Combination Antihypertensive)
Pathways
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.